Juno Therapeutics Gmbh

Memorial Sloan Kettering Cancer Center

Editas Medicine, Inc.

Blythe D Sather

Yan Chen

Steven M Shamah

Csaba Pazmany

Jui Dutta-Simmons

Collin Hauskins

Rebecca Wu

Kimberly Harrington

Eric L Smith

Semih Ullah Tareen

Rupesh Amin

Aye Chen

Melissa Works

Ruth Salmon

Stefan Ponko

Mariana Cota Stirner

Erik Hess

Cyr De Imus

Audrey Olshefsky

Jon Jones

Stephen Jacob Goldfless

Cameron Brandt

Brian J Belmont

Hyam I Levitsky

Kendall M Mohler

Yue Jiang

Alexandra Croft

Gordon Grant Welstead

Christopher Heath Nye

James Sissons

David Jeffrey Huss

Stephen Michael Burleigh

Dean Y Toy

Timothy G Johnstone

Haley Peper

Christopher Borges

David Koppstein

Hieu Nguyen

Sonia Timberlake

Queenie Vong

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.

HPV-specific binding molecules

Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.

Antibodies and chimeric antigen receptors specific for B-cell maturation antigen

Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.

Provided are engineered cells for adoptive therapy, including NK cells and T cells. Also provided are compositions for engineering and producing the cells, compositions containing the cells, and methods for their administration to subjects. In some embodiments, the cells contain genetically engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and costimulatory receptors. In some embodiments, the cells include receptors targeting multiple antigens. In some embodiments, the cells include repression of one or more gene product, for example, by disruption of a gene encoding the gene product. In some embodiments, a gene encoding an antigen recognized by the engineered antigen receptor is disrupted, reducing the likelihood of targeting of the engineered cells. In some embodiments, the antigen recognized by the engineered antigen receptor is related to a tumor antigen recognized by the engineered antigen receptor.

Engineered cells for adoptive cell therapy

Growing community of inventors

Seattle, WA, United States of America

Blythe D Sather